Astellas Pharma created a breakthrough product in the area of treatment for MRSA and cSSSI. With a unique dual mechanism of action (MOA), Vibativ could more efficaciously fight severe infections caused by methicillin-resistant staphylococci.
The client wanted this campaign to be aggressive and arresting. The focus was to be around the dual MOA.
This is a second concept that the client brought into focus group testing, and it scored very high. The arresting visual clearly communicated 2 apex predators representing the duo MOA ready to kill MRSA.